Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

Recruiting now · Not applicable

Conditions studied: NSCLC

In brief

To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spread

Key facts

Study ID: NCT02354274
Run by: Olfred Hansen
People needed: 330
Starts: 2015-01-01
Expected to finish: 2029-10-01
Last updated by the study team: 2022-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with histologically or cytologically proven locally advanced NSCLC stage IIB to IIIB
Performance status 0-1
Able to comply with treatment and follow study and follow-up procedures
Women must have negative pregnancy test
Signed, informed consent
Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two normal tissue must be available

You may not qualify if…

Any unstable systemic disorder (including infection , unstable angina, congestive heart failure , severe liver , kidney or metabolic disease)
Need for nasal oxygen
Former thoracic radiotherapy, unless there is no significant overlap with previous fields
Any other active malignant disease
Unable to take oral medications or needing intravenous nutrition
Ulcer
Nursing women

Where it is running

Herlev University Hospital — Herlev, Denmark (enrolling)
Aarhus University Hospital — Aarhus, Denmark (enrolling)
Department of Oncology, Odense University Hospital — Odense, Denmark (enrolling)
Department of Oncology, Vejle Hospital — Vejle, Denmark (enrolling)
Department of Oncology, Naestved Hospital — Næstved, Denmark
Rigshospitalet — Copenhagen, Denmark
Aalborg University Hospital — Aalborg, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.